MEDI 342 |
| N-Acetyl-S-(p-chlorophenylcarbamoyl)cysteine (NACC) was identified as a metabolite of sulofenur, an anticancer agent reported by Lilly Research Laboratories against solid tumors. NACC was found to exhibit anticancer activity against a colon cancer cell line and low toxicity against CV-1 cells - a normal monkey kidney cell line. More interestingly, our preliminary data revealed that the compound caused an accumulation of the colon cancer cells in the G0/G1 phase of the cell cycle thus preventing the cells from entering the S phase. This is a different anticancer mechanism than most other cell cycle active chemotherapeutic agents that block cancer cells at the S or M phase. Various analogs of NACC have been synthesized. The synthesis and anticancer activity evaluation of these compounds will be presented.
|
|
Poster Session
7:00 PM-9:00 PM, Wednesday, August 22, 2007 BCEC -- Exhibit Hall - B2, Poster
Division of Medicinal Chemistry |